Syngene teams with immuno-oncology firm to provide ‘greater value-added services’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags: Syngene, Immuno-oncology, Monoclonal antibodies, Contract research organization

Syngene International has inked a non-exclusive partnering agreement with the emerging immuno-oncology company Zumutor Biologics after collaborating for more than a year.

Zumutor Biologics Inc. is an immuno-oncology company focusing on novel monoclonal antibody (mAb) therapeutics against innate immunity targets.

Per the partnering agreement, the contract research organization (CRO) Syngene will screen target antigens against Zumutor’s human antibody libraries to identify and characterize novel antibody clones – which it will further develop towards novel biotherapeutics programs.

“Syngene has been collaborating with Zumutor for over a year, providing immuno-oncology services. During the course of this collaboration, we got a better understanding of Zumutor’s proprietary human library platform that complemented our existing capabilities in antibody discovery,”​ said Manoj Nerurkar, PhD, COO, Syngene International.

“Through this partnership, we saw an opportunity to provide greater value-added services to our global clients,”​ he told us.

Nerurkar said the company does not anticipate any additional investments for this partnership.

Investment and expansion

In March of this year, Syngene secured​ a multi-year agreement with GSK through which the companies will focus on accelerating the discovery of new drug candidates using the CRO’s discovery services platform.

As part of the agreement, Sygene said it would be establishing a customized discovery research laboratory to support the projects.

Additionally, following an expanded research collaboration with Amgen in 2017, the CRO announced​ an expansion to double the footprint of its research and development center in Bangalore, India.

Related topics: Bio Developments, Bio-Outsourcing

Related news

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers